ABSTRACT
Immunosuppressive therapy is the treatment of choice in children with acquired severe aplastic anemia (AA) and no HLA-matched family donor. The paper presents results of a multicenter study of 63 children with AA treated with rabbit antithymocyte globulin (r-ATG) and cyclosporine A as the first line treatment in the years 1996-2012. Therapeutic effects were evaluated at Days 112, 180, and 360. At Day 112, remission was achieved in 28 out of the 63 patients (44.4 %), complete remission in 10 patients (15.9 %), and partial remission in 18 (28.5 %). At Day 180, 31 patients (49.2 %) were in remission including 15 cases in complete (23.8 %), and 16 cases in partial remission (25.4 %). One year after therapy onset, 34 patients (64.9 %) were in remission including 24 patients (38.0 %) in complete and 10 (15.9 %) in partial remission. Relapse occurred in 4 patients, from 8 months up to 2 years and 2 months after remission. One child, 5 years after remission, was diagnosed with paroxysmal nocturnal hemoglobinuria. The estimated 10-year overall survival rate and 10-year event-free survival rate were 67 % and 57 %, respectively.
Subject(s)
Anemia, Aplastic/therapy , Antilymphocyte Serum/therapeutic use , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Adolescent , Anemia, Aplastic/immunology , Anemia, Aplastic/mortality , Animals , Child , Child, Preschool , Female , Humans , Infant , Male , Rabbits , Retrospective Studies , Treatment OutcomeABSTRACT
Significant improvement in the prognosis of malignant germ cell tumors in children is related to the introduction of multi-drug chemotherapy based on cisplatin. The most effective combinations of drugs are BEP and BVP; in advanced tumors they make it possible to employ radical surgical procedures.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Germinoma/drug therapy , Bleomycin/administration & dosage , Child , Cisplatin/administration & dosage , Combined Modality Therapy , Etoposide/administration & dosage , Humans , Prognosis , Vinblastine/administration & dosageABSTRACT
Successful treatment of olfactory neuroblastoma is more often described in less advanced tumors and mostly in adults. Fewer presentations concern successful chemotherapy in advanced stages of the disease.
